Tokyo, Japan – 21st February 2007: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), a biopharmaceutical company, today announces that its collaborative project SD118, which is under development for the treatment of neuropathic pain, has successfully completed regulatory pre-clinical studies and will now be progressed into Phase 1 clinical trials.
SD118 is being jointly developed with NeuroDiscovery Ltd (ASX Code: NDL) and its wholly owned subsidiary NeuroSolutions Ltd under a Collaboration Agreement concluded in June 2006. SD118 was previously under investigation in Japan for a different indication and now, following re-profiling, has demonstrated its potential as a new oral neuropathic pain therapy.
Sosei will shortly make a Clinical Trial Application in the UK to facilitate the Phase 1 trials commencement. Mr Shinichi Tamura, President & CEO of Sosei, said: "I am delighted that we have been able to announce the completion of the pre-clinical work for SD118, further validating Sosei’s expertise in successfully re-profiling compounds for new indications and its ability to provide potential compounds to replenish its pipeline.”